【佳学基因检测】PCR基因检测ADA基因有突变,如何解读?
基因检测的序列名称:
ADA
人体基因序列变化与疾病表征数据库中的基因代码:
100
人体基因序列数据库中国际交流名称全称
adenosine deaminase
中国数据库中基因全称:腺苷脱氨酶基因检测报告英文版基因简介
This gene encodes an enzyme that catalyzes the hydrolysis of adenosine to inosine. Various mutations have been described for this gene and have been linked to human diseases. Deficiency in this enzyme causes a form of severe combined immunodeficiency disease (SCID), in which there is dysfunction of both B and T lymphocytes with impaired cellular immunity and decreased production of immunoglobulins, whereas elevated levels of this enzyme have been associated with congenital hemolytic anemia. [provided by RefSeq, Jul 2008]
基因突变所影响的基因信息
该基因编码催化腺苷水解为肌苷的酶。已经对该基因描述了各种突变,这些突变与人类疾病有关。这种酶的缺乏会导致一种严重的联合免疫缺陷病(SCID),其中B和T淋巴细胞均功能障碍,细胞免疫力降低,免疫球蛋白生成减少,而这种酶的水平升高与先天性溶血性贫血有关。[由RefSeq提供,2008年7月]
国际国内该碱基因序列的其他英语文字母简称:
正在通过基因解码技术进行收集、查证并编辑,请关注佳学基因,获得及明更新的人类基因序列变化与疾病表征数据库的更新内容
基因解码对该基因序列在细胞核中的染色体所给予的编号:
该基因序列位于人类第20号染色体上。
基因解码对基因序列的正确定位
该基因序列在GRCh37版本中的起始位置坐标为:43248160;结束位置坐标为:43280376。该基因序列在GRCh38版本中的起始位置坐标为:44619519;结束位置坐标为:44651758。正确的基因信息定位是基因检测和对检测结果进行正确解读的关键。
佳学基因解码对该基因的功能分类:国际版
Enzymes/ENZYME proteins/Hydrolases
基因解码对该基因的功能分类:中文版
酶/酶蛋白/水解酶
结构与功能基因解码所揭示的该基因在细胞内发挥作用的场所(国际版):
Plasma membrane(Supported)Cytosol(Approved)
结构与功能基因解码所揭示的该基因发挥作用的细胞内位置(中文版):
质膜胞质溶胶
该基因序列变化后增加的疾病风险(国际版):
Absent specific antibody response; Congenital absence of thymus; Reduced red cell adenosine deaminase activity; SCID Due to ADA Deficiency, Early-Onset; Severe combined immunodeficiency due to adenosine deaminase deficiency; Immunoglobulin IgG2 deficiency; Spinal Cord Diseases; Absence of B cells; Absent B cells; Anterior rib cupping; Somatic mosaicism; Diffuse mesangial sclerosis (disorder); Low B cell count; Omenn Syndrome; Elevated IgE; Atypical lymphocyte observed; Decreased IgM; Desquamation of skin soon after birth; Hyperemia; Recurrent fungal infections; Autoimmune hemolytic anemia; B-Cell Lymphomas; Recurrent viral infections; Severe Combined Immunodeficiency; Immunoglobulin A deficiency (disorder); Diffusely thickened skin; Pachyderma; Reactive airway disease; Autoimmune thrombocytopenia; Idiopathic thrombocytopenia; Immune thrombocytopenic purpura; Exfoliative dermatitis; Eosinophilia; Chronic diarrhea; Absence of eyebrows; Aplasia/Hypoplasia of the eyebrow; Sparse or absent eyebrows; Sparse/absent eyebrows; Paranasal Sinus Diseases; Abnormality of pelvic girdle bone morphology; Lymphopenia; Sinusitis; Increased susceptibility to bacterial infections; Prone to bacterial infection; Recurrent bacterial infection; Platyspondyly; Pruritus; Lymphadenopathy; Edema; Dry skin; Xerosis; Pneumonia; Alopecia; Asthma; Diarrhea; Fever; Splenomegaly; Lung Neoplasms; Hepatomegaly; Autistic Disorder; Failure to gain weight; Pediatric failure to thrive; Liver Cirrhosis, Experimental; Autosomal recessive predisposition
如果该基因突变后,风险可能增加的疾病类型(中文版):
缺乏特异性抗体反应;先天性缺乏胸腺;红细胞腺苷脱氨酶活性降低; SCID 由于 ADA 缺乏早发;由于腺苷脱氨酶缺乏引起的严重联合免疫缺陷;免疫球蛋白 IgG2 缺乏症;脊髓疾病; B细胞缺失; B 细胞缺失;前肋拔罐;体细胞嵌合;弥漫性系膜硬化(紊乱); B 细胞计数低;预兆综合症; IgE 升高;观察到非典型淋巴细胞; IgM 降低;出生后不久皮肤脱屑;充血;反复性真菌感染;自身免疫性溶血性贫血; B 细胞淋巴瘤;反复性病毒感染;严重联合免疫缺陷;免疫球蛋白 A 缺乏症(疾病);皮肤普遍增厚;厚皮病;反应性气道疾病;自身免疫性血小板减少症;特发性血小板减少症;免疫性血小板减少性紫癜;剥脱性皮炎;嗜酸性粒细胞增多;慢性腹泻;没有眉毛;眉毛发育不全/发育不全;眉毛稀疏或缺失;稀疏/没有眉毛;鼻旁窦疾病;骨盆带骨形态异常;淋巴细胞减少症;鼻窦炎;增加对细菌感染的易感性;易受细菌感染;反复性细菌感染;鸭嘴兽;瘙痒;淋巴结肿大;浮肿;皮肤干燥;干燥症;肺炎;脱发;哮喘;腹泻;发烧;脾肿大;肺肿瘤;肝肿大;自闭症;未能增加体重;儿科发育不良;肝硬化实验性的;常染色体隐性易感性
GWAS基因检测所建立的与该基因的疾病关联(国际版):
正在通过基因解码技术进行收集、查证并编辑,请关注佳学基因,获得及明更新的人类基因序列变化与疾病表征数据库的更新内容
GWAS基因检测所解码的该基因突变会增加风险的疾病种类(中文版):
正在通过基因解码技术进行收集、查证并编辑,请关注佳学基因,获得及明更新的人类基因序列变化与疾病表征数据库的更新内容
以该基因做靶点的药物(国际版):
Pentostatin (Zinc ion binding);Dipyridamole (Zinc ion binding);FR221647 (Zinc ion binding);6-Hydroxy-7,8-Dihydro Purine Nucleoside (Zinc ion binding);FR117016 (Zinc ion binding);FR236913 (Zinc ion binding);6-Hydroxy-1,6-Dihydro Purine Nucleoside (Zinc ion binding);FR233623 (Zinc ion binding);FR239087 (Zinc ion binding);FR230513 (Zinc ion binding);1-Deaza-Adenosine (Zinc ion binding);Purine Riboside (Zinc ion binding);(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol (Zinc ion binding);1-((1R)-1-(HYDROXYMETHYL)-3-{6-[(3-PHENYLPROPANOYL)AMINO]-1H-INDOL-1-YL}PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE (Zinc ion binding);1-{(1R,2S)-2-HYDROXY-1-[2-(2-NAPHTHYLOXY)ETHYL]PROPYL}-1H-IMIDAZONE-4-CARBOXAMIDE (Zinc ion binding);1-((1R,2S)-1-{2-[2-(4-CHLOROPHENYL)-1,3-BENZOXAZOL-7-YL]ETHYL}-2-HYDROXYPROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE (Zinc ion binding)
针对该基因所产生的突变,可能有正确效果的药物(中文版):
喷司他丁(锌离子结合);双嘧达莫(锌离子结合);FR221647(锌离子结合);6-羟基-7,8-二氢嘌呤核苷(锌离子结合);FR117016(锌离子结合);FR236913(锌离子结合);6-羟基-1,6-二氢嘌呤核苷(锌离子结合);FR233623(锌离子结合);FR239087(锌离子结合);FR230513(锌离子结合);1-脱氮腺苷(锌离子结合) ;Purine Riboside (Zinc ion binding);(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol (Zinc ion binding);1-((1R)-1- (HYDROXYMETHYL)-3-{6-[(3-PHENYLPROPANOYL)AMINO]-1H-INDOL-1-YL}PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE (Zinc ion binding);1-{(1R,2S) -2-HYDROXY-1-[2-(2-NAPHTHYLOXY)ETHYL]PROPYL}-1H-IMIDAZONE-4-CARBOXAMIDE (Zinc ion binding);1-((1R,2S)-1-{2-[2- (4-氯苯基)-1,3-苯并恶唑-7-YL]乙基}-2-羟丙基)-1H-咪唑-4-甲酰胺(锌离子结合)